Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Mar
7
2023
Comments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 2023 Epstein Becker & Green, P.C.
Jan
21
2016
No Duty to Accommodate Medical Marijuana Use in New Mexico Epstein Becker & Green, P.C.
May
2
2023
Unpacking Averages: Success Rates for FDA FOIAs by Topic and Requester Epstein Becker & Green, P.C.
Mar
18
2020
#WorkforceWednesday: COVID-19 Pandemic, Election Rules Challenged, EEOC Limits GC’s Authority Epstein Becker & Green, P.C.
Aug
8
2023
The FTC Finalizes Changes to Endorsement Guides Epstein Becker & Green, P.C.
Aug
23
2023
SuperValu’s Effect on the FCA Scienter Standard and Impact to Future Litigation Epstein Becker & Green, P.C.
Sep
5
2023
Unpacking Averages: How Accurate Do Class II Medical Devices Need to Be to Obtain 510(k) Clearance? Epstein Becker & Green, P.C.
Jul
14
2020
FDA to Resume Domestic Inspections with New Safety Measures after Temporary Pause Due to COVID-19 Health and Safety Concerns Epstein Becker & Green, P.C.
Jan
19
2024
Sponsored Genetic Testing Programs: Compliance Considerations Following DOJ False Claims Act Settlement Epstein Becker & Green, P.C.
Oct
31
2017
A Growing Trend In Favor of Medical Marijuana Users in the Employment Context Epstein Becker & Green, P.C.
Feb
1
2018
Federal Judge Stays Enforcement of New York City’s Newly-Enacted Fast Food Deductions Law Epstein Becker & Green, P.C.
Aug
18
2021
How Can Companies in the Health Care and Life Sciences Industries Strengthen Their Cybersecurity Posture? [PODCAST] Epstein Becker & Green, P.C.
Feb
14
2019
Remote Prescribing Trends in Telehealth Epstein Becker & Green, P.C.
Feb
24
2015
CMS Takes a Measured Approach to Medicare Advantage and Part D Plan Payment Rates and Policy Changes for 2016: Increased Part D Drug Costs Set the Stage for Higher Beneficiary Premiums Epstein Becker & Green, P.C.
Oct
13
2022
Four Years After EKRA: Reminders for Clinical Laboratories Epstein Becker & Green, P.C.
Sep
9
2019
HHS and FDA Propose Action Plan for the Importation of Certain Foreign Drugs into the United States Epstein Becker & Green, P.C.
Mar
1
2023
Unpacking Averages: Exploring New Data on FDA Responses to FOIA Requests Epstein Becker & Green, P.C.
Apr
4
2023
Is CMS Ignoring the Realities of Biopharmaceutical Costs? Epstein Becker & Green, P.C.
Apr
26
2023
The Legal Battle Over Mifepristone Epstein Becker & Green, P.C.
Mar
19
2020
FDA Issues Temporary Guidance on Food Supplier Verification Audit Requirements Epstein Becker & Green, P.C.
Aug
1
2023
Unpacking Averages: Analyzing the Relationship Between MDRs and Recalls Epstein Becker & Green, P.C.
Sep
12
2023
HHS Recommends Re-Classification of Marijuana as a Schedule III Controlled Substance – A Bellwether for the Future of Cannabis-ness Epstein Becker & Green, P.C.
Jun
17
2020
DTC Pricing Disclosure Rule Invalidated Epstein Becker & Green, P.C.
Mar
8
2024
BioMarin Subpoena Potentially Signals Continued Investigations into Sponsored Testing Programs Epstein Becker & Green, P.C.
Nov
5
2020
Reminder: Cannabis Companies Must Comply with Federal Workplace Anti-Discrimination Laws Too Epstein Becker & Green, P.C.
Mar
30
2018
Recent State Court Decisions and FDA Inaction Leave Brand Name Manufacturers Uncertain about Liability for Updating Safety Labeling: The Impact of the “Sameness” Standard Epstein Becker & Green, P.C.
Aug
18
2021
Vaccine Mandates, Mandate Bans, Wage and Hour Nomination Stalls – Employment Law This Week [VIDEO] Epstein Becker & Green, P.C.
Nov
29
2018
HRSA Establishes January 1, 2019 Effective Date for 340B Ceiling Price and Civil Monetary Penalty Rule Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins